November 5, 2021 10:34 AM EDTUpdated 10:50 AM

Dems' $100B deal reduced further: Medicare drug price negotiations pushed to 13 years for biologics

Zachary Brennan

Senior Editor

House Democrats are on the cusp of passing two major pieces of Biden’s agenda Friday, but Medicare drug price negotiations — once the centerpiece of the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Dems' $100B deal reduced further: Medicare drug price negotiations pushed to 13 years for biologics

Zachary Brennan

Senior Editor

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

AbbVie doubles down on siRNA with $335M upfront bet on ADARx

GSK to pay $1.2B upfront to snag Boston Pharma’s mid-stage MASH hope

Novo turns to Septerna for oral obesity medicines in deal worth up to $2.2B

SK, Carlyle bolster bluebird bio bid; Therini Bio raises $39M

Lack of detail in Trump's drug price plan raises more questions than answers

PBM overhaul and drug price negotiations make the cut in Republicans' tax bill

Dem­s' $100B deal re­duced fur­ther: Medicare drug price ne­go­ti­a­tions pushed to 13 years for bi­o­log­ics

Senior Editor

Sign up to read this article for free.

more like this

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Dems' $100B deal reduced further: Medicare drug price negotiations pushed to 13 years for biologics